Rebecca G Kim1, Rohit Loomba2, Larry J Prokop3, Siddharth Singh4. 1. Division of Internal Medicine, Department of Medicine, University of California at San Diego, La Jolla, California. 2. Division of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, California; NAFLD Research Center, Department of Medicine, University of California at San Diego, La Jolla, California; Division of Epidemiology, Department of Family Medicine and Public Health, University of California at San Diego, La Jolla, California. 3. Department of Library Services, Mayo Clinic, Rochester, Minnesota. 4. Division of Gastroenterology, Department of Medicine, University of California at San Diego, La Jolla, California; Division of Biomedical Informatics, Department of Medicine, University of California at San Diego, La Jolla, California. Electronic address: sis040@ucsd.edu.
Abstract
BACKGROUND & AIMS: Statins have been variably shown to decrease risk and complications of chronic liver diseases (CLDs). We performed a systematic review and meta-analysis to evaluate the association between statins and risk of cirrhosis and related complications in patients with CLDs. METHODS: Through a systematic literature search up to March 2017, we identified 13 studies (3 randomized trials, 10 cohort studies) in adults with CLDs, reporting the association between statin use and risk of development of cirrhosis, decompensated cirrhosis, improvements in portal hypertension, or mortality. Pooled relative risk (RR) estimates with 95% confidence interval (CIs) were calculated using random effects model. Grading of Recommendations Assessment, Development and Evaluation criteria were used to assess quality of evidence. RESULTS: Among 121,058 patients with CLDs (84.5% with hepatitis C), 46% were exposed to statins. In patients with cirrhosis, statin use was associated with 46% lower risk of hepatic decompensation (4 studies; RR, 0.54; 95% CI, 0.46-0.62; I2 = 0%; moderate-quality evidence), and 46% lower mortality (5 studies; RR, 0.54; 95% CI, 0.47-0.61; I2 = 10%; moderate-quality evidence). In patients with CLD without cirrhosis, statin use was associated with a nonsignificant (58% lower) risk of development of cirrhosis or fibrosis progression (5 studies; RR, 0.42; 95% CI, 0.16-1.11; I2 = 99%; very-low-quality evidence). In 3 randomized controlled trials, statin use was associated with 27% lower risk of variceal bleeding or progression of portal hypertension (hazard ratio, 0.73; 95% CI, 0.59-0.91; I2 = 0%; moderate-quality evidence). CONCLUSIONS: Based on a systematic review and meta-analysis, statin use is probably associated with lower risk of hepatic decompensation and mortality, and might reduce portal hypertension, in patients with CLDs. Prospective observational studies and randomized controlled trials are needed to confirm this observation.
BACKGROUND & AIMS: Statins have been variably shown to decrease risk and complications of chronic liver diseases (CLDs). We performed a systematic review and meta-analysis to evaluate the association between statins and risk of cirrhosis and related complications in patients with CLDs. METHODS: Through a systematic literature search up to March 2017, we identified 13 studies (3 randomized trials, 10 cohort studies) in adults with CLDs, reporting the association between statin use and risk of development of cirrhosis, decompensated cirrhosis, improvements in portal hypertension, or mortality. Pooled relative risk (RR) estimates with 95% confidence interval (CIs) were calculated using random effects model. Grading of Recommendations Assessment, Development and Evaluation criteria were used to assess quality of evidence. RESULTS: Among 121,058 patients with CLDs (84.5% with hepatitis C), 46% were exposed to statins. In patients with cirrhosis, statin use was associated with 46% lower risk of hepatic decompensation (4 studies; RR, 0.54; 95% CI, 0.46-0.62; I2 = 0%; moderate-quality evidence), and 46% lower mortality (5 studies; RR, 0.54; 95% CI, 0.47-0.61; I2 = 10%; moderate-quality evidence). In patients with CLD without cirrhosis, statin use was associated with a nonsignificant (58% lower) risk of development of cirrhosis or fibrosis progression (5 studies; RR, 0.42; 95% CI, 0.16-1.11; I2 = 99%; very-low-quality evidence). In 3 randomized controlled trials, statin use was associated with 27% lower risk of variceal bleeding or progression of portal hypertension (hazard ratio, 0.73; 95% CI, 0.59-0.91; I2 = 0%; moderate-quality evidence). CONCLUSIONS: Based on a systematic review and meta-analysis, statin use is probably associated with lower risk of hepatic decompensation and mortality, and might reduce portal hypertension, in patients with CLDs. Prospective observational studies and randomized controlled trials are needed to confirm this observation.
Authors: Gordon Guyatt; Andrew D Oxman; Shahnaz Sultan; Jan Brozek; Paul Glasziou; Pablo Alonso-Coello; David Atkins; Regina Kunz; Victor Montori; Roman Jaeschke; David Rind; Philipp Dahm; Elie A Akl; Joerg Meerpohl; Gunn Vist; Elise Berliner; Susan Norris; Yngve Falck-Ytter; Holger J Schünemann Journal: J Clin Epidemiol Date: 2012-04-27 Impact factor: 6.437
Authors: J A Tobert; G D Bell; J Birtwell; I James; W R Kukovetz; J S Pryor; A Buntinx; I B Holmes; Y S Chao; J A Bolognese Journal: J Clin Invest Date: 1982-04 Impact factor: 14.808
Authors: O Hernández-Perera; D Pérez-Sala; J Navarro-Antolín; R Sánchez-Pascuala; G Hernández; C Díaz; S Lamas Journal: J Clin Invest Date: 1998-06-15 Impact factor: 14.808
Authors: Juan G Abraldes; Candid Villanueva; Carles Aracil; Juan Turnes; Manuel Hernandez-Guerra; Joan Genesca; Manuel Rodriguez; Jose Castellote; Juan Carlos García-Pagán; Ferran Torres; Jose Luis Calleja; Agustin Albillos; Jaime Bosch Journal: Gastroenterology Date: 2016-01-14 Impact factor: 22.682
Authors: Tracey G Simon; Ann-Sofi Duberg; Soo Aleman; Hannes Hagstrom; Long H Nguyen; Hamed Khalili; Raymond T Chung; Jonas F Ludvigsson Journal: Ann Intern Med Date: 2019-08-20 Impact factor: 25.391
Authors: Zobair M Younossi; Rohit Loomba; Mary E Rinella; Elisabetta Bugianesi; Giulio Marchesini; Brent A Neuschwander-Tetri; Lawrence Serfaty; Francesco Negro; Stephen H Caldwell; Vlad Ratziu; Kathleen E Corey; Scott L Friedman; Manal F Abdelmalek; Stephen A Harrison; Arun J Sanyal; Joel E Lavine; Philippe Mathurin; Michael R Charlton; Naga P Chalasani; Quentin M Anstee; Kris V Kowdley; Jacob George; Zachary D Goodman; Keith Lindor Journal: Hepatology Date: 2018-07 Impact factor: 17.425
Authors: Elizabeth K Speliotes; Maya Balakrishnan; Lawrence S Friedman; Kathleen E Corey Journal: Clin Gastroenterol Hepatol Date: 2018-04-21 Impact factor: 11.382